The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Final CLL-FRAIL analysis supports acalabrutinib in elderly and frail patients with CLL
Florian Simon, MD, University Hospital Cologne, Cologne, Germany, discusses the final analysis of the CLL-FRAIL trial (NCT04883749) of acalabrutinib in patients with chronic lymphocytic leukemia (CLL) who are ≥80 years old or considered frail. He highlights more than three years of follow-up and reviews the durable efficacy, favorable tolerability, and sustained improvements in frailty and quality of life. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So with the current update on the CLL-FRAIL trial, which is the final analysis of this trial, we’ve concluded the trial last year and we now have more than three years of follow-up and finally some mature data on how this treatment is tolerated, how efficacious it is and most importantly how well patients do under this treatment, not just with regards to adverse events, but also with quality of life...
So with the current update on the CLL-FRAIL trial, which is the final analysis of this trial, we’ve concluded the trial last year and we now have more than three years of follow-up and finally some mature data on how this treatment is tolerated, how efficacious it is and most importantly how well patients do under this treatment, not just with regards to adverse events, but also with quality of life. And what I found really encouraging was that not only are the Kaplan-Meier curves pretty impressive, especially for this age group with a median age of 81 years, where we see an overall survival above 80% after three years, which is great in this age group. But we also see a lasting improvement in the frailty which the patients report themselves. They’re actually fitter after six months of treatment and remain fit. And with regards to their quality of life, we’re seeing a substantial improvement, especially in the group of patients who are frail at the beginning of the trial. So those with a obviously quite extensive disease burden, these are the patients who are actually improving a lot and who do well on the treatment and continue to do well. So this was really encouraging to see that the trial produced long-term results which show a durable response to the treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
